PRESS RELEASE

Stockholm, Sweden, 8 March 2016



Sobi™ announces new date for Annual General Meeting of shareholders

On 26 February 2016 Swedish Orphan Biovitrum AB (publ) (Sobi™) announced that Chairman Bo Jesper Hansen informed Sobi's nomination committee that he will not stand for re-election at the 2016 Annual General Meeting of shareholders (AGM). It was also announced that the nomination committee will propose that the shareholders elect Håkan Björklund, PhD, as the new Chairman of the Board for Sobi.

In order to allow for Håkan Björklund to attend the AGM the Board of Sobi has decided to change the date for the 2016 AGM from 19 May 2016 to 24 May 2016. A formal notification for the AGM will be published in due course. More information about the AGM is available under the corporate governance section on Sobi's webpage, www.sobi.com.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primary focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2015, Sobi had total revenues of SEK 3.2 billion (USD 385 M) and approximately 700 employees. The share (STO:SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations
Oskar Bosson, Head of Communications
+46 70 410 71 80
oskar.bosson@sobi.com

Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
+1 347-224-0819, +1 212-579-0506, +46 8 697 2135
jorgen.winroth@sobi.com

The information was submitted for publication at 08:00 CET on 8 March 2016.